Trials / Completed
CompletedNCT05205525
Delayed Antibiotic Therapy in Non-severe Ventilator Acquired Pneumonia (VAP)
Aggressive Versus Restrictive Initiation of Antimicrobial Treatment in Critically Ill Patients With Suspected Ventilator Acquired Pneumonia Without Severity : a Before and After Observational Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 87 (actual)
- Sponsor
- Nantes University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This retro-prospective monocentric observational study compare the impact of the implementation of a restrictive (delayed) versus aggressive (immediate) antibiotic strategy for Ventilator Acquired Pneumonia suspicion without severity symptoms.
Detailed description
Ventilator acquired pneumonia (VAP) is the leading cause of nosocomial infection in intensive care patients, and has been associated with increased antibiotic consumption, increased morbidity and mortality. VAP diagnosis is difficult due to subjective or non-specific criteria. Delaying antibiotic treatment for VAP suspicion without severity symptoms raises question since the probability of VAP diagnosis, as well as the risk of delaying treatment, is very uncertain. It may nonetheless limit the environmental impact of antibiotic use which is a public health concern. We compared antibiotic sparing and patient outcome, before and after the implementation of a restrictive (delayed) antibiotic strategy versus an aggressive (immediate) antibiotic strategy in VAP suspicion without severity symptoms.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Restrictive antibiotic strategy | Implementation of a restrictive (delayed) antibiotic strategy in Ventilator Acquired Pneumonia suspicion without severity symptoms. |
| OTHER | Aggressive antibiotic strategy | Implementation of an aggressive (immediate) antibiotic strategy in Ventilator Acquired Pneumonia suspicion without severity symptoms. |
Timeline
- Start date
- 2022-01-06
- Primary completion
- 2023-01-28
- Completion
- 2023-01-28
- First posted
- 2022-01-25
- Last updated
- 2023-03-08
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT05205525. Inclusion in this directory is not an endorsement.